Precision AQ - Investor Relations & External Communications

In case you missed it, Eyepoint CEO Dr. Jay Duker discussed the Company’s exciting opportunity to bring a differentiated treatment option, DURAVYU to patients with wet AMD. Dr. Duker shared key insights into the potential competitive advantages of DURAVYU, including a potent efficacy profile with a rapid onset, and a fully bioerodible and safe delivery mechanism designed for extended durability and sustained therapeutic levels. Access the replay here to learn more about how EyePoint is advancing DURAVYU through Phase 3 trials: https://lnkd.in/g2-g5WW8

The past 2+ years have forced biotech companies to rethink their investor strategy and communications. Fundraising is taking longer and engaging the right audiences—investors, analysts, the media, and strategic partners—has never been more critical. What’s working? - Clear, compelling storytelling that makes your science investable  - Consistent engagement with the right institutional investors  - Messaging that builds confidence in both the clinical proof of concept and commercial viability of a company The companies winning in this market aren’t just ‘waiting it out’—they’re doubling down on IR and external communications to stay ahead. If you’re ready to sharpen your investor messaging and drive the right conversations, let’s talk. #BiotechIR #InvestorRelations #BiotechFinance 

Investors are saying the quiet part out loud: “We’re being extra selective, and here’s what we need to see.” In a market where every dollar counts, investors aren’t just looking at your science—they’re evaluating your entire narrative. The biotech companies securing funding today are: - Communicating a clear path to value creation (not just great data)  - Proactively addressing burn rate and capital efficiency  - Engaging investors long before they need to raise Investor sentiment shifts fast. If your IR strategy isn’t evolving, you’re already behind. Let’s make sure your story is getting heard—and getting results. https://lnkd.in/gErDp543 #InvestorRelations #BiotechFunding #BiotechInvestors #IRStrategy

Pedaling with purpose! Last night, our team hit the bikes for Cycle for Survival, riding strong in the fight against rare cancers. The energy, determination, and team spirit were unmatched—we’re proud to support this incredible cause and grateful to be part of a community that’s making a real impact. #CycleForSurvival #Teamwork #BeatingRareCancers #Blackstone #MSKCC

Nothing like a little biotech brilliance in Boston! The team had a fantastic week at the #CowenHealthcareConference —reconnecting, strategizing, and raising a glass to the future of innovation. Grateful for the conversations, the connections, and the continued inspiration this industry brings. Until next time! #Biotech #investorrelations #PrecisionAQ #Boston

Esperion CEO, Sheldon Koenig, MBA, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event last month in San Francisco to discuss Esperion’s progress advancing innovative medicines that help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. Learn more about Esperion’s global impact on reducing the risk of cardiovascular disease in Precision AQ’s “Access to the Best and Brightest” series!     #Esperion #ESPR #PrecisionAQ #CVRiskReduction #LipidLurkers 

Precision Medicine Group CEO Margaret Keegan was interviewed at the JP Morgan conference and discussed why one customer found a right-size CRO to be better than a big CRO, micro applications for AI and how passion for the customer is a tangible differentiator. Get more in this short video!

ProMIS™ Neurosciences, Inc. CEO, Neil Warma, sat down with Precision AQ EVP & Managing Director, Hannah Deresiewicz, during the Precision AQ Corporate Access Event in San Francisco to discuss the Alzheimer’s disease landscape and the progress of ProMIS’ lead candidate, PMN310.     PMN310 is a humanized monoclonal antibody designed to selectively target toxic oligomers of amyloid-beta, which are widely recognized to be a major driver of Alzheimer’s progression. PMN310’s selective binding to toxic Aβ oligomers and not to plaque or monomers differentiates it from other drugs currently on the market or in development.      Last week, ProMIS initiated dosing in multiple patients in their Phase 1b PRECISE-AD trial, marking a significant milestone for the company. ProMIS expects to share six-month interim results in the first half of 2026 with topline results anticipated in the second half of 2026.     Tune in to learn more about ProMIS’ groundbreaking work in Precision AQ’s “Access to the Best and Brightest” series!     #ProMISNeurosciences #PMN #PrecisionAQ #NeurodegenerativeDiseases #JPM2025 #AlzheimersDisease #AD 

🌎 Where We'll Be for March March is shaping up to be a busy month for Precision AQ! Our teams will be attending some of the top conferences in healthcare and pharma, and we're looking forward to connecting and exchanging ideas with industry leaders. ✨ Fun Fact: According to the Centers for Medicare & Medicaid Services, national health expenditures are projected to reach $6.8 trillion by 2025, accounting 20.1% of the nation's GDP. Got a conference you're looking forward to? Drop a line in the comments and let us know which event(s) you'll be at. We look forward to seeing you there! See the full list of events the AQ team will have a presence at in the coming months: https://lnkd.in/eaqQvtNz #PharmaMarketing #HealthcareStrategy #HealthcareLeaders #LifeSciences

This January in San Francisco, Precision AQ EVP & Managing Director Hannah Deresiewicz sat down with Spur Therapeutics CEO Michael Parini at the J.P. Morgan Healthcare Conference to discuss how Spur is pushing the boundaries of #genetherapy through a redefined approach of developing gene therapies for treatment of serious chronic diseases.     Featuring in this video is one of Precision AQ’s “Best and Brightest” in Spur Therapeutics who highlight FLT201, the Company’s adeno-associated virus gene therapy candidate in Gaucher disease, and how the exciting Phase 1/2 clinical data has paved the way for a Phase 3 trial to begin later this year.